Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Scutellaria lateriflora*, commonly known as American skullcap, is a perennial herb native to North America traditionally used in herbal medicine for its sedative, anxiolytic, and anticonvulsant properties. Its therapeutic effects are primarily attributed to a diverse profile of flavonoids, including baicalin, baicalein, wogonin, and oroxylin A. Recent clinical and preclinical research has explored its efficacy in treating primary insomnia, managing stress-induced cortisol release, and reducing gingival inflammation when used in combination with other botanical extracts. Additionally, its constituent flavonoids have demonstrated potential anti-inflammatory, antioxidant, and neuroprotective activities, with investigations extending into oncology (e.g., breast cancer and leukemia) and bone health. It is often administered as an aqueous or hydroethanolic extract in dietary supplements or homeopathic preparations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Scutellaria lateriflora.